Substance / Medication

Nirmatrelvir

Overview

Active Ingredient
nirmatrelvir
RxNorm CUI
2587892

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Evaluating the safety and efficacy of nirmatrelvir-ritonavir therapy in pregnant women with COVID-19: a systematic review and meta-analysis.
Hassan Omar, Elbhairy Aya Abdulkarim, Siam Aya Magdy et al. · Eur J Clin Pharmacol · 2025
PMID: 39948217Meta-Analysis
Nirmatrelvir/ritonavir treatment for COVID-19: an economic value systematic literature review.
Mugwagwa Tendai, Marcano Belisario José, Hartley Louise et al. · J Med Econ · 2025
PMID: 41134222Meta-Analysis
Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis.
Amani Behnam, Amani Bahman · Expert Rev Anti Infect Ther · 2024
PMID: 38457124Meta-Analysis
Nirmatrelvir/ritonavir for COVID-19: an overview of systematic reviews.
Cruciani Mario, Pati Ilaria, Masiello Francesca et al. · J Antimicrob Chemother · 2024
PMID: 38084876Meta-Analysis
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies.
Mesfin Yonatan M, Blais Joseph E, Kibret Kelemu Tilahun et al. · J Antimicrob Chemother · 2024
PMID: 38817046Meta-AnalysisFull text (PMC)
Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron: An updated meta-analysis.
Ombelet Sien, Castanares-Zapatero Diego, Desimpel Fabian et al. · J Med Virol · 2024
PMID: 38376947Meta-Analysis
Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: A systematic review and meta-analysis.
Cheema Huzaifa A, Jafar Uzair, Sohail Aruba et al. · J Med Virol · 2023
PMID: 36606609Meta-Analysis
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis Stefanie, Metzendorf Maria-Inti, Kuehn Rebecca et al. · Cochrane Database Syst Rev · 2023
PMID: 38032024Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Nirmatrelvir (substance)
SNOMED CT
1332141006
UMLS CUI
C5545149
RxNorm CUI
2587892

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.